Category - Feature

Feature

MAIA Biotechnology aiming to extend lives through new cancer treatment class with telomere-targeting agent

MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim...

April 14, 2026

Feature

Cell Technologies targeting joint disease with stem cell-based therapies

Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and...

April 7, 2026

Feature

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...

March 17, 2026

Feature

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

March 3, 2026

Feature

MediWound healing without surgery through a pineapple-derived enzymatic approach

MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...

February 24, 2026

Feature

Imviva closing the gap between autologous and off-the-shelf CAR-T

Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...

February 17, 2026

Feature

Astrocyte delivering first-in-class approach to brain injury neuroprotection

Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...

February 3, 2026

Feature

First Ascent changing the cancer care narrative with functional precision medicine

Closely held First Ascent Biomedical is working to redefine how oncologists select therapies by pairing genomics with a proprietary live-cell testing platform that evaluates how an individual patient’s cancer responds...

January 20, 2026

Feature

In conversation with Leslie Loveless, CEO and managing partner of Slone Partners

For more than two decades, Slone Partners has maintained a dedicated focus on leadership recruitment for life sciences and healthcare organizations. The company’s co-CEO and managing partner, Leslie Loveless, has been...

January 13, 2026

Feature

PetVivo improving the lives of pets and athlete animals through joint health and mobility

PetVivo Holdings (PetVivo Animal Health) (OTCQX: PTEV; OTCID: PETVW) is adapting human regenerative therapies for the management of osteoarthritis (OA) and other joint disorders in companion and athlete animals. The...

January 6, 2026

Category - Feature

Subscribe